

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: December 17, 2009

Electronic Signature for Cristin Howley Cowles, Ph.D.: /Cristin Howley Cowles/

Used in Lieu of PTO/SB/08A/B
(Based on PTO 01-08 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number	10/622,932-Conf. #3572
Filing Date	July 18, 2003
First Named Inventor	Subhashis Banerjee
Art Unit	1643
Examiner Name	David J. Blanchard
Attorney Docket Number	117813-18705

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A1*	5,958,953		07-07-1998	Marfat et al.	
A2*	6,537,549		03-25-2003	Tobinick	
A3*	6,090,382		07-18-2000	Salfeld et al.	
A4*	6,258,562		07-10-2001	Salfeld et al.	
A5*	6,595,015		01-27-2003	Salfeld et al.	
A6*	7,588,761		09-15-2009	Salfeld et al.	
A7*	US 2003-0219438 A1		11-27-2003	Salfeld et al.	
A8*	US 2009-01155205 A1		06-18-2009	Salfeld et al.	
A9*	US 2004-0033228 A1		02-19-2004	Krause et al.	
A10*	US 2003-0206898 A1		11-06-2003	Fischkoff et al.	
A11*	US 2009-0110679 A1		04-30-2009	Li et al.	
A12*	US 2009-0017472 A1		01-15-2009	Stuhlmuller et al.	
A13*	US 2009-0258018 A1		10-15-2009	Medich et al.	
A14*	US 2009-0239259 A1		09-24-2009	Hsieh et al.	
A15*	US 2009-0226530 A1		09-10-2009	Lassner et al.	
A16*	US 2009-0271164 A1		10-29-2009	Peng et al.	
A17*	US 2004-0126372 A1		07-01-2004	Banerjee et al.	
A18*	US 2004-0131614 A1		07-08-2004	Banerjee et al.	
A19*	US 2004-0126373 A1		07-01-2004	Banerjee et al.	
A20*	US 2004-0151722 A1		08-05-2004	Banerjee et al.	
A21*	US 2008-0193466 A1		08-14-2008	Banerjee et al.	
A22*	US 2004-0136990 A1		07-15-2004	Banerjee et al.	
A23*	US 2004-0219142 A1		11-04-2004	Banerjee et al.	
A24*	US 2004-0136989 A1		07-15-2004	Banerjee et al.	
A25*	US 2003-0012786 A1		01-16-2003	Teoh et al.	
A26*	US 2003-0161828 A1		08-28-2003	Abdelghany et al.	
A27	7,223,394		05-29-2007	Salfeld et al.	
A28	7,541,031		06-02-2009	Salfeld et al.	
A29	US 2003-0235585 A1		12-25-2003	Fischkoff et al.	
A30	US 2006-0153846 A1		07-13-2006	Krause et al.	
A31	US 2004-0009172 A1		01-15-2004	Fischkoff et al.	
A32	US 2004-0166111 A1		08-26-2004	Kaymakcalan et al.	
A33	US 2006-0009385 A1		01-12-2006	Hoffman et al.	
A34	US 2009-0304682 A1		12-10-2009	Hoffman et al.	
A35	US 2006-0083741 A1		04-20-2006	Hoffman et al.	
A36	US 2007-0041905 A1		02-22-2007	Hoffman et al.	
A37	US 2007-0081996 A1		04-12-2007	Hoffman et al.	
A38	US 2007-0071747 A1		03-29-2007	Hoffman et al.	

Examiner
Signature

Date
Considered

¹EXAMINER Initial # reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²CITE NO. Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IWF. ³Applicant's unique citation designation number (optional). ⁴See Kinds of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁵Enter Office that issued the document, by the two-letter code (WIPO Standard 2). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B./

Used in Lieu of PTO/SB/08A/B
(Based on PTO 01-08 version)

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/622,932-Conf. #3572
(Use as many sheets as necessary)				Filing Date	July 18, 2003
Sheet	2	of	4	First Named Inventor	Subhashis Banerjee
				Art Unit	1643
				Examiner Name	David J. Blanchard
				Attorney Docket Number	117813-18705

A39	US 2007-0172897 A1	07-26-2007	Maksymowych et al.	
A40	US 2007-0292442 A1	12-20-2007	Wan et al.	
A41	US 2008-0166348 A1	07-10-2008	Kupper et al.	
A42	US 2009-0028794 A1	01-29-2009	Medich et al.	
A43	US 2008-0118496 A1	05-22-2008	Medich et al.	
A44	US 2009-0123378 A1	05-14-2009	Wong et al.	
A45	US 2008-0131374 A1	06-05-2008	Medich et al.	
A46	US 2008-0311043 A1	12-18-2008	Hoffman et al.	
A47	US 2008-0227136 A1	09-18-2008	Pla et al.	
A48	US 2007-0202104 A1	08-30-2007	Banerjee et al.	
A49	US 2004-0136991 A1	07-08-2004	Banerjee et al.	
A50	5,656,272	08-12-1997	Le et al.	
A51	6,177,077	01-23-2001	Tobinick	
A52	6,448,380	08-30-2001	Rathjen	
A53	6,451,983	08-30-2001	Rathjen	
A54	6,498,237	09-20-2001	Rathjen	
A55	6,593,458	07-15-2003	Rathjen	
A56	7,070,775	07-31-2003	Le et al.	
A57	7,192,584	02-21-2002	Le et al.	
A58	7,276,239	06-29-2006	Le et al.	

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²CITE NO.: These application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. ³ Applicants unique citation designation number (optional). ⁴See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁵Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁷Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B./

Used in Lieu of PTO/SB/08A/B
(Based on PTO 01-08 version)

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/622,932-Conf. #3572
<i>(Use as many sheets as necessary)</i>				Filing Date	July 18, 2003
Sheet	3	of	4	First Named Inventor	Subhashis Banerjee
				Art Unit	1643
				Examiner Name	David J. Blanchard
				Attorney Docket Number	117813-18705

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² -Number ³ -Kind Code ⁴ (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁵
B1	WO 97/23131	06-14-1997	04-14-1997	Basf Aktiengesellschaft		
B2	WO 98/22460	05-28-1998		Darwin Discovery Ltd.		
B3	WO 02/12502	08-07-2001		Centocor, Inc.		
B4	JP2001302542	10-31-2001		Tenabe Seiyaku Co.	(English abstract only)	
B5	JP11127852	05-18-1999		Nippon Kayaku KK	(English abstract only)	

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ⁵
C1	Baugh, John A. et al., "Mechanisms for modulating TNF α in immune and inflammatory disease," <i>Current Opinion in Drug Discovery & Development</i> , Vol. 4(5):635-650 (2001)						
C2	Bodmer, Mark et al., "Preclinical review of anti-tumor necrosis factor monoclonal antibodies," <i>Critical Care Medicine</i> , Vol. 21(10):S441-S446 (1993)						
C3	Eliwski "Infliximab for the treatment of severe pustular psoriasis." <i>J. Am. Acad. Dermatol.</i> 2002 Nov;47(5):796-7						
C4	Grom, Alexei A. et al., "Patterns of Expression of Tumor Necrosis Factor α , Tumor Necrosis Factor, and Their Receptors in Synovia of Patients with Juvenile Rheumatoid Arthritis and Juvenile Spondyloarthropathy." <i>Arthritis & Rheumatism</i> , Vol. 39(10):1703-1710 (1996)						
C5	Iyer et al. "Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy." <i>Br. J. Dermatol.</i> 2002 Jan;146(1):118-21						
C6	Kamarashev et al. "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept." <i>Dermatology</i> . 2002;205(2):213-6						
C7	Kietz et al. "Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis..." <i>Journal of Rheumatology</i> , 28(2):360-362, February 2001.						
C8	Kirby et al. "Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate." <i>Clin. Exp. Dermatol.</i> 2001 Jan;26(1):27-9						

Examiner Signature	Date Considered

*EXAMINER: Initial # reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those applications which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the USPTO's Application Filing Database (AFD). ** Kind Code: Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B./

Used in Lieu of PTO/SB/08A/B
(Based on PTO 01-08 version)

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/622,932-Conf. #3572
<i>(Use as many sheets as necessary)</i>				Filing Date	July 18, 2003
Sheet	4	of	4	First Named Inventor	Subhashis Banerjee
				Art Unit	1643
				Examiner Name	David J. Blanchard
				Attorney Docket Number	117813-18705

C9	Mang <i>et al.</i> "Response of severe psoriasis to Infliximab." <i>Dermatology</i> . 2002;204(2):156-7
C10	Mease <i>et al.</i> "Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial." <i>Lancet</i> . 2000 Jul 29;356(9227):385-90
C11	Newland <i>et al.</i> "Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type." <i>Int. J. Dermatol.</i> 2002 Jul;41(7):449-52
C12	O'Quinn <i>et al.</i> "The effectiveness of tumor necrosis factor α antibody (infliximab) in treating recalcitrant psoriasis: A report of 2 cases." <i>Arch. Dermatol.</i> 2002 May;138(5):644-8.
C13	Russell-Jones <i>et al.</i> "High-dose interferon and the U.K. guidelines for cutaneous melanoma." <i>Br. J. Dermatol.</i> 2002 Oct;147(4):832-4
C14	Schopf <i>et al.</i> "Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor α , infliximab." <i>J. Am. Acad. Dermatol.</i> 2002 Jun;46(6):886-91
C15	Takematsu, H.: "Absence of tumor necrosis factor-alpha in suction blister fluids and stratum corneum from patients with psoriasis." : <i>Arch Dermatol Res</i> . 1989;281(6):398-400.
C16	Asadullah, K. <i>et al.</i> "A high prevalence of cytomegalovirus antigenaemia in patients with moderate to severe chronic plaque psoriasis: an association with systemic tumor necrosis factor α overexpression." <i>Br. J. Dermatol.</i> 1999 141(1):94-102
C17	Chaudhari, U. <i>et al.</i> "Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial." <i>Lancet</i> 2001 357(9271):1842-7.
C18	Marks, JD <i>et al.</i> "By-Passing Immunization: Building High Affinity Human Antibodies By Chain Shuffling." <i>Nature Biotechnology</i> 1992 10:779-783.
C19	Cavagna, L. <i>et al.</i> "Infliximab in the treatment of adult Still's disease refractory to conventional therapy." <i>Clin Exp Rheumatol</i> /2001 19(3):329-332.
C20	Kraetsch, H. <i>et al.</i> "Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences." <i>Ann Rheum Dis</i> 2001 60(Suppl. 3):ii55-ii57
C21	Baeten, D. <i>et al.</i> "Immunomodulatory Effects of Anti-Tumor Necrosis Factor α Therapy on Synovium in Spondylarthropathy." <i>Arthritis & Rheumatism</i> 2001 44(1):186-195

Examiner Signature	/David Blanchard/	Date Considered	04/09/2010
--------------------	-------------------	-----------------	------------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO. Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. *Applicant's name and address should be provided in the communication. Use the WIPO Standard ST 16 if possible. www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B./